Gilead's selonsertib fails PhIII in less sick NASH patients — to no one's surprise

Gilead's selonsertib fails PhIII in less sick NASH patients — to no one's surprise

Source: 
Endpoints
snippet: 

The prospects of Gilead’s top late-stage NASH drug selonsertib grew dim when it kicked off Phase III readouts with a flop. Two months later, the company conceded that a second, much similar trial has also failed.